Skip to main content

Current information


Aristo Pharma announces an equity financing agreement with VaRi Bioscience

News teaser VaRi Bioscience


“We are very happy to collaborate with Aristo Pharma GmbH. The collaboration enables us to conduct Phase IIB for VR102, a long-acting 3-month vaginal ring for the local treatment of vulvovaginal atrophy”, explains Klaus Nickisch, CEO of VaRi Bioscience GmbH. “We are glad to join forces with VaRi Bioscience GmbH, a company led by experts in female health with extensive experience in the vaginal ring technology and in the space of hormonal therapy. Together with VaRi Bioscience GmbH, Aristo Pharma GmbH can expand its portfolio of branded products in Europe and is fostering its ambition to become a provider of pharmaceutical products with a higher specialty focus”, states Benjamin Breitfeld, Head of Global Portfolio Management & Business Development at Aristo Pharma. 

About VaRi Bioscience GmbH 

VaRi Bioscience GmbH is an innovative German biotech company that is pioneering novel approaches to serve high unmet medical needs in various therapeutic areas of Female Health. The company focuses on the discovery and development of innovative products centered around its unique, IP-protected approach of novel drug delivery concepts. 

Go to top